talks

invited presentations, symposia, and workshops

  • Mar 2025: Intellectual Property, Covid-19, and the Next Pandemic. London School of Economics Law School. Discussant at book launch. London, UK.

  • Feb 2025: The First Mile: Production Markets and Global Access to Medicines. London School of Economics Health Policy. London, UK.

  • Oct 2024: COVID-19 and pharmaceutical manufacturing: estimating effects on API markets for essential medicines and in-demand, speculatively repurposed medicines. Program on Regulation, Therapeutics, and Law (PORTAL), Harvard Medical School. Boston, USA.

  • Mar 2024: Estimating sustainable cost-based prices for diabetes medicines. Centre for Heath Economics, University of York. York, UK.

  • Nov 2023: Considering generic market developments in EML review processes. Meeting on Revising procedure for updating WHO’s Model List of Essential Medicines, World Health Organization. Geneva, Switzerland.

  • Oct 2023: Delinking incentives to invest from government granted monopolies: how would it work? With Rohit Malpani, James Love (KEI), and Dean Baker (CEPR). People’s Vaccine Alliance (Oxfam) panel (held virtually).

  • Oct 2023: COVID-19 and pharmaceutical manufacturing: estimating effects on API markets for essential medicines and in-demand, speculatively repurposed medicines. Department of Economics and Related Studies Seminar, University of York. York, UK.

  • Oct 2020: Fair or excessive? Estimating confidential pharmaceutical manufacturing costs and applications in law. Intellectual Property Law Discussion Group (IPDG), Oxford University. Oxford, UK.

  • Apr 2017: Are prices of medicines influenced by production costs? Production costs for the medicines on the WHO Essential Medicines List [Keynote]. Pharmaceutical Pricing and Reimbursement Information (PPRI) Network Annual Meeting. Stockholm, Sweden.

  • Nov 2016: ¿Cuál es el costo para producir un medicamento? Congreso internacional sobre acceso a medicamentos, tecnologías médicas y derechos humanos. Buenos Aires, Argentina.

  • Apr 2016: Declaration on patent protection: regulatory sovereignty under the TRIPS Agreement. The Max Planck Institute for Innovation and Competition and the University of South Africa College of Law. Pretoria, South Africa.

peer-reviewed presentations

  • May 2024: Are competition fines effective deterrents to excessive pricing of medicines? Evidence from a landmark competition case in the United Kingdom. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (PPRI) Conference. Vienna, Austria.

  • May 2024: Cost analysis of TB-PRACTECAL, a multicentre phase 2/3 trial in drug-resistant TB. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (PPRI) Conference. Vienna, Austria.

  • May 2024: COVID-19 and pharmaceutical manufacturing: estimating effects on markets for raw materials for essential medicines and in-demand, speculatively repurposed medicines. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (PPRI) Conference. Vienna, Austria.

  • June 2023: Evidence of Excessive Pricing of Pharmaceutical Ingredients for Medicines Speculatively Repurposed as COVID-19 Therapeutics.
    • This paper won the Program Chair Award in Prescription Drugs at the American Society of Health Economists (ASHE) Conference. St Louis, MO.

  • July 2023: Evidence of Excessive Pricing of Pharmaceutical Ingredients for Medicines Speculatively Repurposed as COVID-19 Therapeutics. International Health Economics Association (IHEA). Cape Town, South Africa.

  • July 2023: COVID-19 and Markets for Pharmaceutical Raw Materials: Estimating Price and Volume Effects and Disparities by Country Income Category. International Health Economics Association (IHEA). Cape Town, South Africa.

  • July 2021: Estimated cost-based generic prices for key ARVs and effect of COVID-19 on manufacturing costs. 11th IAS Conference on HIV Science (held virtually).

  • July 2020: Cost-based estimated prices for key HIV, HCV, and MDR-TB medicines. 23rd International AIDS Conference (held virtually).

  • Nov 2019: The road to elimination of hepatitis C: Costs per cure fall to US $32 per person. American Association for the Study of Liver Diseases Liver Meeting. Boston, USA.

  • Sept 2018: Countering information asymmetry in price negotiations: estimating the costs of production of medicines. Fifth Global Congress on Intellectual Property and the Public Interest. Washington DC, USA.

  • Apr 2017: Analysis of current prices for anti-infectives in the World Health Organization Essential Medicines List in the UK, South Africa, and India, compared to cost of production. 27th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria.

  • Apr 2017: How to calculate fair prices of antimicrobials - methodological and practical issues. 27th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria.

  • Jan 2017: Unexplained rises in UK cancer drug prices between 2011 and 2016. European Cancer Congress. Amsterdam, The Netherlands.

  • Jan 2017: Potential price reductions for cancer medicines on the WHO Essential Medicines List. European Cancer Congress. Amsterdam, The Netherlands.